



# Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2022 [Japanese GAAP]

May 12, 2022

Listing: Tokyo Stock Exchange

Company name: Medical Data Vision Co., Ltd.

Securities code: 3902 URL <https://www.mdv.co.jp/>

Representative: (Title) President

(Name) Hiroyuki Iwasaki

Inquiries: (Title) Executive Officer and General Manager of

(Name) Masahiro Kihara

Tel: +81-3-5283-6911

Corporate Planning Division

Scheduled date to file quarterly report: May 13, 2022

Scheduled date to commence dividend payments: -

Preparation of supplementary material on quarterly financial results : Yes

Holding of quarterly financial results briefing : Yes (for institutional investors and analysts)

(Yen amounts are rounded down to millions, unless otherwise noted)

1. Consolidated financial results for the first quarter of the fiscal year ending December 31, 2022 (from January 1, 2022 to March 31, 2022)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes)

	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
First quarter of FY ending December 31, 2022	1,511	-	470	-	461	-	313	-
First quarter of FY ended December 31, 2021	1,429	37.1	454	98.4	453	98.5	309	103.7

(Note) Comprehensive income First quarter of fiscal year ending December 31, 2022 314 million yen [-%]  
First quarter of fiscal year ended December 31, 2021 316 million yen [108.3%]

	Basic earnings per share		Diluted earnings per share	
	Yen		Yen	
First quarter of FY ending December 31, 2022	8.17		8.17	
First quarter of FY ended December 31, 2021	7.86		-	

(Note) 1. The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29) and related implementation guidance have been applied from the beginning of the fiscal year ending December 2022. Consolidated earnings for the 1st quarter of the fiscal year ending December 2022, therefore, are the amount after applying such accounting standard and related implementation guidance, presenting no change from the previous corresponding period.

2. Diluted earnings per share for the three months ended March 31, 2021 are not presented as there are no potential shares.

(2) Consolidated financial position

	Total assets		Net assets		Equity-to-asset ratio	
	Millions of yen		Millions of yen		%	
As of March 31, 2022 (1Q FY2022)	4,446		2,960		65.3	
As of December 31, 2021 (FY2021)	5,534		4,205		75.1	

(Reference) Equity As of March 31, 2022 2,902 million yen  
As of December 31, 2021 4,156 million yen

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen				
FY ended December 31, 2021	-	0.00	-	5.60	5.60
FY ending December 31, 2022	-				
FY ending December 31, 2022 (forecast)		0.00	-	6.00	6.00

(Note) Revision of the latest released dividend forecast : None

### 3. Consolidated earnings forecasts for the fiscal year ending December 31, 2022 (from January 1, 2022 to December 31, 2022)

(Percentages indicate year-on-year changes)

Full year	Net sales		Operating income		Ordinary income		Net income attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
	6,300	-	1,599	-	1,600	-	1,098	-	28.74

- (Notes) 1. Revision of the latest released earnings forecasts : None  
 2. The Accounting Standard for Revenue Recognition (ASBJ Statement No. 29) and related implementation guidance have been applied from the beginning of the fiscal year ending December 2022. The above consolidated earnings forecasts therefore are the amount after applying such accounting standard and related implementation guidance, presenting no year-on-year changes.  
 3. The Company purchased 763,400 treasury shares from January 1, 2022 to January 25, 2022 based on the resolution of the Board of Directors held on December 22, 2021. Basic earnings per share for the consolidated earnings forecasts takes into account the impact of the purchase of treasury shares.

#### \* Notes

- (1) Changes in significant subsidiaries during the three months ended March 31, 2022 (changes in specified subsidiaries resulting in changes in scope of consolidation) : None

Newly included: - companies (Company name) , Excluded: - companies (Company name)

- (2) Application of special accounting treatment to the preparation of quarterly consolidated financial statements : None

- (3) Changes in accounting policies, changes in accounting estimates, and restatement

- (i) Changes in accounting policies due to revisions to accounting standards and other regulations : Yes  
 (ii) Changes in accounting policies other than (i) above : None  
 (iii) Changes in accounting estimates : None  
 (iv) Restatement : None

(Notes) For more details, please refer to “(3) Notes to quarterly consolidated financial statements (Change in accounting policies) in 2. Quarterly consolidated financial statements and Key notes” on page 4 of the attached materials.

- (4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)	As of March 31, 2022	40,027,526 shares	As of December 31, 2021	40,027,526 shares
(ii) Number of treasury shares at the end of the period	As of March 31, 2022	1,830,678 shares	As of December 31, 2021	1,067,278 shares
(iii) Average number of shares outstanding during the period (cumulative quarterly period )	First quarter of FY ending December 31, 2022	38,348,612 shares	First quarter fiscal year ended December 31, 2021	39,402,919 shares

\* Quarterly financial results reports are exempt from a quarterly review conducted by certified public accountants or an audit corporation.

#### \* Proper use of earnings forecasts, and other special matters

The forward-looking statements, including earnings forecasts, contained in this material are based on information currently available to the Group and on certain assumptions deemed to be reasonable.